Premium
Treatment Outcome of Overactive Bladder Patients Receiving Antimuscarinic Therapy for More than One Year
Author(s) -
HSIAO ShengMou,
LIN HoHsiung,
KUO HannChorng
Publication year - 2018
Publication title -
luts: lower urinary tract symptoms
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.451
H-Index - 15
eISSN - 1757-5672
pISSN - 1757-5664
DOI - 10.1111/luts.12136
Subject(s) - overactive bladder , medicine , therapeutic effect , constipation , international prostate symptom score , blurred vision , comorbidity , adverse effect , urology , surgery , lower urinary tract symptoms , prostate , alternative medicine , pathology , cancer
Objectives Details on the therapeutic effects of long‐term antimuscarinic therapy have not been reported. Thus, the aim of this study is to evaluate the detailed long‐term therapeutic effect of antimuscarinic therapy. Methods All consecutive patients who visited the urologic outpatient clinics of a medical center for treatment of overactive bladder syndrome and received antimuscarinic therapy of 12 months or more were retrospectively reviewed. All medical records, including the Overactive Bladder Symptom score ( OABSS ), the modified Indevus Urgency Severity Scale and the International Prostate Symptoms score ( IPSS ) questionnaires, and uroflowmetry parameters were reviewed at each visit. Results A total of 140 patients had received 12 months or more of antimuscarinic therapy. Sustained therapeutic effects were observed by persistent decreases of IPSS ‐storage score, IPSS ‐total score and OABSS score. Moreover, the maximum flow rate did not change over time. A temporary increase in postvoid residual volume and decrease in voiding efficiency were found, but these parameters improved over long‐term visits. Side‐effects were observed in 81 patients (57.9%) and included dry mouth ( n = 58, 41.4%), constipation ( n = 48, 34.3%) and blurred vision ( n = 4, 2.9%); all side‐effects were tolerable. Patients aged 75 years or more ( n = 94) had a higher comorbidity rate ( n = 46, 48.9%) before treatment but generally exhibited similar therapeutic effects as overall patients; elderly patients could also tolerate side‐effects. Conclusion Sustained therapeutic effects were observed in patients who received 12 months or more of antimuscarinic therapy, even in elderly patients. In addition, side‐effects in patients receiving long‐term therapy were also common but tolerable.